[Form 4] 60 Degrees Pharmaceuticals, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Insider option grant and ownership change at 60 Degrees Pharmaceuticals — Kristen Landon, the company’s Chief Operating Officer, was granted 4,167 stock options with an exercise price of $6.85. The options vest in five equal annual tranches beginning December 31, 2024, and have a 10-year maximum term. After the grant, Landon beneficially owns 4,167 underlying shares directly. The filing notes it was submitted late due to an administrative error and that all figures were retroactively adjusted for a 1-for-5 reverse stock split effected by the issuer.

Positive

• Executive alignment: Grant increases the COO’s equity stake, aligning incentives with shareholder value creation.
• Standard vesting: Time-based vesting over five years supports retention and long-term focus.

Negative

• Late disclosure: The Form 4 was filed late due to an administrative error, indicating a compliance lapse.
• Small grant size: The option count (4,167) is modest and unlikely to materially drive company performance.

Insights

Financial Analyst

TL;DR: A modest option grant aligns COO incentives with shareholders but is unlikely to be materially value-driving.

The grant of 4,167 options at a $6.85 strike increases executive alignment with equity performance while diluting shareholders minimally given the small option count. Vesting over five years ties retention to multi-year performance. The 10-year term is standard for employee options. The late Form 4 filing is an administrative compliance lapse but does not change the economics of the grant. The retroactive adjustment for a 1-for-5 reverse split is an important technical detail for share counts and comparable analysis.

Corporate Governance Expert

TL;DR: Standard compensation action with governance flags from a late disclosure.

The structure — time-based vesting in equal annual tranches and a 10-year term — follows common practice for retention-focused equity awards. Reporting a late Form 4 is a governance control weakness that should be remediated to maintain transparency. The disclosure does correctly state the split adjustment, which preserves accuracy of beneficial ownership records.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landon Kristen

(Last) (First) (Middle)

C/O 60 DEGREES PHARMACEUTICALS, INC.

1025 CONNECTICUT AVENUE NW SUITE 1000

(Street)

WASHINGTON DC 20036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)(2)(3)	$6.85	09/26/2024		A		4,167		(1)	09/26/2034	Common Stock	4,167	$0	4,167	D

Explanation of Responses:

1. The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant.

2. This Form 4 is being filed late due to an inadvertent administrative error.

3. All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025.

	/s/ Kristen Landon	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did Kristen Landon acquire according to the Form 4?

The Form 4 reports a grant of 4,167 stock options exercisable into common stock.

What is the exercise price and term of the options in the filing?

The options have an exercise price of $6.85 and a maximum term of 10 years from grant.

How do the options vest for the COO?

The options vest in five equal annual tranches, with the first vesting on December 31, 2024.

Was there any adjustment to the reported figures?

Yes, all reported information was retroactively adjusted to reflect a 1-for-5 reverse stock split effected by the issuer.

Does the filing indicate any compliance issues?

The filing states it was submitted late due to an inadvertent administrative error.